| Literature DB >> 26472962 |
Jun Go1, Ji-Eun Kim1, Eun-Kyoung Koh1, Sung-Hwa Song1, Ji-Eun Seung1, Chan-Kyu Park1, Hyun-Ah Lee1, Hong-Sung Kim1, Jae-Ho Lee1, Beum-Soo An1, Seung-Yun Yang1, Yong Lim2, Dae-Youn Hwang1.
Abstract
To evaluate the hepatotoxicity and nephrotoxicity of Galla Rhois (GR) toward the liver and kidney of ICR mice, alterations in related markers including body weight, organ weight, urine composition, liver pathology and kidney pathology were analyzed after oral administration of 250, 500 and 1,000 mg/kg body weight/day of gallotannin-enriched extract of GR (GEGR) for 14 days. GEGR contained 68.7±2.5% of gallotannin, 25.3±0.9% of gallic acid and 4.4±0.1% of methyl gallate. Also, the level of malondialdehyde (MDA), a marker of lipid peroxidation, was decreased with 19% in the serum of high dose GEGR (HGEGR)-treated mice. The body and organ weight, clinical phenotypes, urine parameters and mice mortality did not differ among GEGR-treated groups and the vehicle-treated group. Furthermore, no significant increase was observed in alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), blood urea nitrogen (BUN) and the serum creatinine (Cr) in the GEGR-treated group relative to the vehicle-treated group. Moreover, the specific pathological features induced by most toxic compounds such as CCl4 were not observed upon liver and kidney histological analysis. Overall, the results of the present study suggest that GEGR does not induce any specific toxicity in liver and kidney organs of ICR at doses of 1,000 mg/kg body weight/day, indicating that this is no observed adverse effect level (NOAEL).Entities:
Keywords: Galla Rhois; gallotannin; hepatotoxicity; histopathology; nephrotoxicity
Year: 2015 PMID: 26472962 PMCID: PMC4602076 DOI: 10.5625/lar.2015.31.3.101
Source DB: PubMed Journal: Lab Anim Res ISSN: 1738-6055
Distribution of three functional components in GEGR
| Items | Gallotannin | Gallic acid | Methyl gallate |
|---|---|---|---|
| Ratio | 68.7±2.5% | 25.3±0.9% | 4.4±0.1% |
The data shown represent the means±SD of three replicates
Figure 1MDA concentration in the serum of ICR mice treated with GEGR. The level of MDA was determined in the serum collected from the whole blood of ICR mice using a lipid peroxidation assay kit. Also, this kit could detect MDA at 0.1 nmole/mg to 20 nmole nmole/mg. Three samples were assayed in triplicate by MDA assay. Data are reported as the mean±SD. a, P<0.05 compared to the vehicle-treated group.
Alteration in the weights of body and organs of ICR mice treated with GEGR
| Organs | Vehicle | LGEGR | MGEGR | HGEGR |
|---|---|---|---|---|
| Body weight (g) | 27.79±1.19 | 27.36±1.84 | 26.67±1.25 | 26.71±1.60 |
| Brain (g) | 0.50±0.02 | 0.49±0.02 | 0.51±0.01 | 0.49±0.02 |
| Ovary (mg) | 17.56±11.12 | 20.43±6.23 | 18.65±3.98 | 20.49±2.04 |
| Kidney (g) | 0.33±0.02 | 0.33±0.04 | 0.31±0.03 | 0.31±0.02 |
| Spleen (g) | 0.11±0.01 | 0.10±0.03 | 0.11±0.01 | 0.10±0.01 |
| Liver (g) | 1.15±0.08 | 1.10±0.11 | 1.04±0.13 | 1.05±0.14 |
| Thymus (g) | 0.08±0.02 | 0.07±0.02 | 0.08±0.02 | 0.07±0.02 |
| Heart (g) | 0.13±0.02 | 0.12±0.01 | 0.13±0.01 | 0.11±0.01 |
| Lung (g) | 0.17±0.02 | 0.19±0.03 | 0.18±0.01 | 0.18±0.02 |
The data shown represent the means±SD of three replicates. Vehicle, vehicle-treated group; LGEGR, low dosage GEGR-treated group; MGEGR, middle dosage GEGR-treated group; HGEGR, high dosage GEGR-treated group.
Alteration in the urine biochemical parameters of ICR mice treated with GEGR
| Parameter | Vehicle | LGEGR | MGEGR | HGEGR |
|---|---|---|---|---|
| Bilirubin (mg/dL) | 0.20±0.274 | 0.25±0.289 | 0.25±0.354 | 0.33±0.224 |
| Urobilinogen (mg/dL) | 0.40±0.548 | 0.50±0.577 | 0.50±0.707 | 0.67±0.548 |
| Leucocytes (WBC/µL) | 50.00±28.86 | 46.25±33.76 | 53.33±37.53 | 41.67±27.39 |
| Protein (mg/dL) | 47.50±35.00 | 65.00±40.41 | 65.50±49.50 | 46.67±46.37 |
| Ketones (mg/dL) | 6.25±2.500 | 8.33±2.887* | 10.00±0.000* | 9.17±2.236* |
| pH | 6.75±1.190 | 7.25±1.190 | 6.00±0.500 | 5.42±0.418 |
| Specific gravity | 1.03±0.003 | 1.03±0.003 | 1.03±0.003 | 1.03±0.003 |
*P<0.05 compared to the vehicle-treated group. The data shown represent the means±SD of three replicates. Vehicle, vehicle-treated group; LGEGR, low dosage GEGR-treated group; MGEGR, middle dosage GEGR-treated group; HGEGR, high dosage GEGR-treated group.
Figure 2Effects of GEGR on liver toxicity in ICR mice. (A) Serum was collected from the abdominal veins of ICR mice and the serum concentrations of ALP, AST, ALT and LDH were then analyzed as described in the Materials and Methods. (B) Liver tissues were stained with H&E and cellular morphology was viewed at 400× magnification. The data shown represent the means±SD of three replicates. Vehicle, vehicle-treated group; LGEGR, low dosage GEGR-treated group; MGEGR, middle dosage GEGR-treated group; HGEGR, high dosage GEGR-treated group. Arrow, hepatocytes; arrow head, Sinusoid.
Figure 3Effects of GEGR on the kidney toxicity in ICR mice. (A) Serum was collected from the abdominal veins of ICR mice and serum concentrations of BUN and CRE were then analyzed as described in the Materials and Methods. (B) Kidney tissues were stained with H&E, and cellular morphology was viewed at 400× magnification. The data shown represent the means±SD of three replicates. Vehicle, vehicle-treated group; LGEGR, low dosage GEGR-treated group; MGEGR, middle dosage GEGR-treated group; HGEGR, high dosage GEGR-treated group. Arrow, Distal convoluted tubules; arrow head, Proximal convoluted tubules; RC, Renal corpuscle.